Insider · CIK 0001586965

Enyedy Mark J

Reports to the SEC for 7 companies · SAN RAFAEL, CA

sec.gov

Transactions

Companies

Filings

CIK

0001586965

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-02	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+7,490 sh	—	—	21,040
2026-05-08	CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC.A Award	Director	AAward	+1,438 sh	$177.62	+$255K	2,384
2025-06-02	CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC. · Stock Options (Right to Buy)A Award	Director	AAward	+2,082 sh	$135.04	+$281K	2,082
2025-06-02	CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC.A Award	Director	AAward	+946 sh	$135.04	+$128K	946
2025-05-20	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+6,650 sh	—	—	13,550
2024-05-21	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+4,720 sh	—	—	6,900
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director, CHIEF EXECUTIVE OFFICER	DDisposition to Issuer	−925K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director, CHIEF EXECUTIVE OFFICER	DDisposition to Issuer	−1.1M sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director, CHIEF EXECUTIVE OFFICER	DDisposition to Issuer	−922K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director, CHIEF EXECUTIVE OFFICER	DDisposition to Issuer	−1.1M sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director, CHIEF EXECUTIVE OFFICER	DDisposition to Issuer	−197K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Restricted Stock UnitD Disposition to Issuer	Director, CHIEF EXECUTIVE OFFICER	DDisposition to Issuer	−140K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Restricted Stock UnitD Disposition to Issuer	Director, CHIEF EXECUTIVE OFFICER	DDisposition to Issuer	−102K sh	—	—	0
2024-02-12	ImmunoGen, Inc.D Disposition to Issuer	Director, CHIEF EXECUTIVE OFFICER	DDisposition to Issuer	−584K sh	—	—	0
2024-02-05	ImmunoGen, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−20.1K sh	$29.28	−$589K	584,397
2024-02-02	ImmunoGen, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+51.2K sh	—	—	604,504
2024-02-02	ImmunoGen, Inc.Restricted Stock UnitM Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−51.2K sh	—	—	102,466
2024-02-01	ImmunoGen, Inc.Restricted Stock UnitA Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+140K sh	—	—	140,357
2023-12-27	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+2,180 sh	—	—	2,180
2023-08-04	ImmunoGen, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−782K sh	—	—	0
2023-08-04	ImmunoGen, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+782K sh	$5.25	+$4.11M	1,223,689
2023-08-04	ImmunoGen, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+22K sh	$4.55	+$100K	1,245,667
2023-08-04	ImmunoGen, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+300K sh	$5.65	+$1.7M	1,545,667
2023-08-04	ImmunoGen, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−992K sh	$16.96	−$16.8M	553,270
2023-08-04	ImmunoGen, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−300K sh	—	—	0
2023-08-04	ImmunoGen, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−22K sh	—	—	196,875
2023-08-03	ImmunoGen, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+1.02M sh	$4.55	+$4.63M	1,461,449
2023-08-03	ImmunoGen, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−186K sh	—	—	196,875
2023-08-03	ImmunoGen, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−831K sh	—	—	218,853
2023-08-03	ImmunoGen, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−2,760 sh	—	—	782,240
2023-08-03	ImmunoGen, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+2,760 sh	$5.25	+$14.5K	444,209
2023-08-03	ImmunoGen, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−1.02M sh	$16.61	−$16.9M	441,449
2023-08-02	ImmunoGen, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+995K sh	$4.55	+$4.53M	1,436,606
2023-08-02	ImmunoGen, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−987K sh	$17.45	−$17.2M	450,085
2023-08-02	ImmunoGen, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−8,636 sh	$18.15	−$157K	441,449
2023-08-02	ImmunoGen, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−995K sh	—	—	382,968
2023-06-30	ImmunoGen, Inc.A Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+5,241 sh	$4.05	+$21.2K	441,449
2023-02-03	ImmunoGen, Inc.Stock Option (right to buy)A Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+922K sh	—	—	922,400
2023-02-03	ImmunoGen, Inc.Restricted Stock UnitA Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+154K sh	—	—	153,700
2022-11-16	LogicBio Therapeutics, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−2,921 sh	—	—	0
2022-11-16	LogicBio Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−12.5K sh	—	—	0
2022-11-14	ImmunoGen, Inc.Stock Option (Right to Buy)A Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+788K sh	—	—	1,181,250
2022-06-30	ImmunoGen, Inc.A Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+3,342 sh	$3.83	+$12.8K	436,208
2022-06-17	LogicBio Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2022-05-20	ImmunoGen, Inc.Stock Option (Right to Buy)A Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+394K sh	—	—	393,750
2022-02-04	ImmunoGen, Inc.Stock Option (right to buy)A Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+1.1M sh	$5.32	+$5.85M	1,100,000
2021-06-30	ImmunoGen, Inc.A Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+3,849 sh	$5.52	+$21.2K	432,866
2021-06-11	LogicBio Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2021-02-05	ImmunoGen, Inc.Stock Option (right to buy)A Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+925K sh	$7.69	+$7.11M	925,000
2021-01-01	LogicBio Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,921 sh	—	—	2,921

Recent filings

Accepted (ET)
Jun 44
Enyedy Mark J0001628280-26-040914
SEC(opens sec.gov)
May 114
Enyedy Mark J0001100682-26-000050
SEC(opens sec.gov)
Jun 44
Enyedy Mark J0001127602-25-016729
SEC(opens sec.gov)
May 224
Enyedy Mark J0001048477-25-000070
SEC(opens sec.gov)
May 234
Enyedy Mark J0001048477-24-000100
SEC(opens sec.gov)
Feb 124
Enyedy Mark J0001104659-24-014715
SEC(opens sec.gov)
Feb 64
Enyedy Mark J0001415889-24-002871
SEC(opens sec.gov)
Feb 54
Enyedy Mark J0001415889-24-002759
SEC(opens sec.gov)
Dec 284
Enyedy Mark J0001048477-23-000072
SEC(opens sec.gov)
Aug 44
Enyedy Mark J0001415889-23-011881
SEC(opens sec.gov)

Companies

Address

C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO STREET

SAN RAFAEL, CA, 94901